Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in SCLP?
Scancell Holdings Plc: THE INVESTMENT CASE

Scancell poised for “significant” year with its immuno-oncology portfolio

"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
newspaper with word cancer magnified
INVESTMENT OVERVIEW: SCLP The Big Picture
Scancell's focus is in the 'hot' area of immuno-oncology

With around 13,000 new cases of melanoma diagnosed annually and 2,000 deaths a year, skin cancer is the fifth most common cancer in the UK.

In fact, recent studies have found that malignant melanoma diagnoses hit 10,000 a year for over 55s alone, compared with just 3,100 cases two decades ago, an increase of 155%.

Dr Anton Alexandroff, a consultant dermatologist at Leicester Royal Infirmary, said the increase was likely due to “reckless” lifestyles and improper protection from the sun, which is the main cause of most skin cancers.

There is hope for those with this deadly type of cancer though, with Scancell Holdings Plc’s (LON:SCLP) SCIB1 immunotherapy continuing to produce remarkable survival data from the ongoing phase I/II clinical trial.

Priming the body to fight cancer

Scancell’s immunotherapy vaccine primes the patient’s immune system to recognise and kill specific cancer cells.

SCIB1 – and now SCIB2 – targets and stimulates existing cells that make up the body’s defence mechanisms, in particular the dendritic cells already present at the site of the cancer.

Dendritic cells are found in all tissues that are in contact with the external environment, such as the skin, lungs and intestines.

The main function of these cells is to process antigens - foreign or toxic material - and present them to the immune system. Once activated, they migrate to the lymph nodes where the antigen is destroyed by the body’s T cells.

“Compelling” clinical trial results so far

At the turn of the year, Scancell reported the “compelling” results of a phase I/II trial of SCIB1, and the immunotherapy has continued to impress since.

Overall, 18 of the 20 stage III/IV melanoma patients with resected disease (i.e. some or all of the tumour has been surgically removed in the past) remain alive and have lived significantly longer than the ‘established norms’.

Of the 16 resected patients who received 2-4 milligram (mg) doses of SCIB1, only six patients have had a recurrence of their disease while only two have died.

READ: SCIB1 continues to produce strong survival data

WATCH: CEO Goodfellow discusses recent £5mln fundraise

The median observation time for this group of patients is edging up towards five years, with seven patients in the trial surviving for longer than that since starting treatment.

Remarkably, four of those have managed to live for that period without having the disease return.

One patient with unresected disease has also been able to survive for longer than five years since starting treatment with SCIB1 despite the disease progressing.

Two of four resected patients who received stronger 8mg doses of SCIB1 have experienced disease recurrence although none have died, Scancell added.

“We are pleased to report that most patients with resected disease enrolled in the SCIB1 clinical trial are still alive and without disease recurrence, including the majority of patients who were previously undergoing continuation treatment,” said chief executive Richard Goodfellow.

Next study will be in the States

Investors have known for a while that next up is a SCIB1/ checkpoint inhibitor combination study which will be carried out in the United States.

A new batch of the drug has been manufactured and will be released for clinical use later this quarter.

That will coincide with the submission of the investigational new drug (IND) application to the US Food and Drug Administration for a phase II trial, which is on track to be submitted before the end of September.

“Our next study, which will be in the US, will assess the potential for an increase in response rate in patients with malignant melanoma when treated with SCIB1 and a checkpoint inhibitor,” said Goodfellow.

What the brokers are saying…

After those initial results back in January, Panmure Gordon analyst Mike Mitchell, in a note to clients, said Scancell was poised for a “significant year”.

He hasn’t changed his tune in the intervening six months either, explaining that today’s (11 July) results should serve as a reminder of the “potential” of the upcoming combination study.

“In our view, the potential for SCIB1, as already demonstrated by the survival data, is remarkable. Most resected Stage III and IV melanoma patients from the SCIB1 Phase 1/2 clinical trial remain alive and without disease recurrence,” said Mitchell.

“On this basis, we consider a SCIB1/checkpoint inhibitor combination offers a compelling prospect both for patients and for Scancell’s ImmunoBody franchise.”

The shares, which are currently changing hands for around 12p, are worth 68p according to the analyst.

Fellow City broker Hardman & Co reiterates the view that there’s a lot of headroom for growth in the Scancell share price.

“Scancell’s proprietary technologies are in the ‘hot’ area of immuno-oncology and targeting markets of significant unmet medical need.

“Given that big pharma is willing to pay handsomely for such validated assets, we foresee considerable upside potential in the shares.”

Not just skin cancer treatments though…

While SCIB1 is furthest along the pipeline, Scancell also has a non-small cell lung cancer (NSCLC) treatment – SCIB2 – which is progressing well.

In fact, the group has recently inked a US collaboration deal with a leading lung cancer foundation that will accelerate the development of the drug.

It is teaming up with the Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J Addario Lung Cancer Foundation to take the SCIB2 cancer vaccine into phase I/II clinical trials.

ALCMI will assist Scancell with the design and development of the study, which is set to get underway in 2018 and complete around 18 months later.

Lung cancer remains one of the most difficult cancers to treat and accounts for more than a quarter of all cancer deaths.

That’s more than breast, prostate and colon cancers combined. Around 228,000 people receive a lung cancer diagnosis in the US alone and more than 160,000 will not survive.

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Related Articles

scientist in a lab
September 27 2017
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"
Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use